The IBCC-led PHERGain clinical trial demonstrates that PET-CT can identify patients with localized HER2-positive breast cancer who could be treated without preoperative chemotherapy
Researchers from the International Breast Cancer Center (IBCC) have led the PHERGain clinical trial that shows that PET-CT could identify around 40% of patients with localized HER2-positive breast cancer who could be spared preoperative chemotherapy. ”This study could mean, in the near future, the end of chemotherapy in a significant percentage of patients with this […]
Pembrolizumab is active on its own but does not improve overall survival in patients with previously treated triple-negative metastatic breast cancer
Pembrolizumab has been shown to be active on its own, but has not been shown to improve overall survival compared to standard chemotherapy treatment in patients with previously treated triple-negative metastatic breast cancer, according to the clinical study KEYNOTE-119, published in The Lancet Oncology. Dr. Javier Cortés, director of the International Breast Cancer Center (IBCC), is […]
Sacituzumab govitecan significantly prolongs overall survival in patients with triple-negative metastatic breast cancer
Barcelona, 22 april 2021 Treatment with sacituzumab govitecan significantly prolongs overall survival in patients with triple-negative metastatic breast cancer, as confirmed by the international trial, ASCENT, published today in the New England Journal of Medicine (NEJM). Dr. Javier Cortés Castán, director of the International Breast Cancer Center (IBCC), has been one of the international leaders […]
Pembrolizumab and chemotherapy, new first-line treatment for metastatic triple-negative breast cancer
Immunotherapy is one of the most important avenues of clinical research for patients with advanced triple-negative breast cancer. This subtype of breast cancer has the worst prognosis and accounts for around 15% of all breast cancer cases diagnosed. Pembrolizumab is a monoclonal antibody which targets the PD-1 receptor, found on the surface of lymphocytes, and […]
Adjuvant treatment with abemaciclib decreases invasive recurrences in patients with RH-positive/HER2-negative early breast cancer at high risk of relapse
The addition of two years of abemaciclib therapy to adjuvant hormone therapy decreases the likelihood of recurrence in patients with RH-positive/HER2-negative localized breast cancer at high risk of relapse, as demonstrated by the MONARCHe clinical study, published in Journal of Clinical Oncology, whose authors include Dr. Javier Cortés, director of the International Breast Cancer Center (IBCC). […]
Dr. Javier Cortés contributes as an expert to developing the 5th International Clinical Guidelines (ABC5), at the 5th International Consensus Conference on Advanced Breast Cancer
Dr. Javier Cortés, director of the International Breast Cancer Center (IBCC), has participated as an expert in the development of the 5th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC5 Guidelines), as part of the 5th International Consensus Conference for Advanced Breast Cancer. This top-level scientific congress was held in Lisbon, Portugal, from 14 […]